Jose Reena Anie, Raja Inbaraj Leeberk, Catherine Vincent Ria, Baskar Adhin, Mathew Renu
Department of Microbiology, Believers Church Medical College Hospital, Thiruvalla, Kerala, India.
Department of Clnical Research, ICMR-National Institute for Research in Tuberculosis, Chennai, India.
Indian J Med Microbiol. 2024 Sep-Oct;51:100709. doi: 10.1016/j.ijmmb.2024.100709. Epub 2024 Aug 24.
The diagnosis of Tuberculosis (TB) has been a challenge till the advent of rapid molecular diagnostic tests. The traditional diagnostic tests have its own limitations with regard to its performance or the turnaround time. Truenat MTB Plus assay, a battery-operated molecular assay developed in India has been introduced for its use in pulmonary TB (PTB). However, the diagnostic accuracy of the assay is not well studied in comparison with Mycobacterial culture, especially for extrapulmonary TB (EPTB).
We aimed at evaluating the diagnostic accuracy of Truenat MTB Plus assay for both PTB and EPTB comparing with culture for adult population.
The specimens from presumptive PTB and EPTB patients were processed for Truenat MTB Plus assay, solid or liquid culture and AFB staining. The electronic data of all the specimen reports collected retrospectively were analysed for the sensitivity and specificity.
Out of the 736 samples which had valid culture reports, 364 (49.4 %) were respiratory and 372 (50.6 %) were extrapulmonary specimens. The test positivity rate for smear microscopy, Truenat MTB Plus assay and culture was 3.7 % (27), 8.2 % (60), 7.1 % (52) respectively. Of the 60 Truenat MTB Plus positive patients with TB, 33 (55 %) were PTB and 27 (45 %) were EPTB. We estimated overall sensitivity and specificity of Truenat MTB Plus as 90 % (95 % CI: 73.4-97.8) and 98. 2 (95 % CI:96-99.3) respectively for the detection of PTB. The overall sensitivity and specificity for EPTB was 81.8 % (95 % CI: 59.7-94.8) and 97.4 % (95 % CI: 95.1-98.8) respectively.
Truenat MTB Plus assay has comparable diagnostic accuracy with other molecular assays. The Truenat MTB Plus assay can be used for the diagnosis of PTB and EPTB, especially in resource limited settings.
在快速分子诊断测试出现之前,结核病(TB)的诊断一直是一项挑战。传统诊断测试在性能或周转时间方面有其自身的局限性。Truenat MTB Plus检测法是印度研发的一种电池供电的分子检测法,已被引入用于肺结核(PTB)的诊断。然而,与分枝杆菌培养相比,该检测法的诊断准确性尚未得到充分研究,尤其是对于肺外结核(EPTB)。
我们旨在评估Truenat MTB Plus检测法对成人PTB和EPTB的诊断准确性,并与培养法进行比较。
对疑似PTB和EPTB患者的标本进行Truenat MTB Plus检测、固体或液体培养以及抗酸杆菌染色。对回顾性收集的所有标本报告的电子数据进行敏感性和特异性分析。
在736份有有效培养报告的样本中,364份(49.4%)为呼吸道标本,372份(50.6%)为肺外标本。涂片显微镜检查、Truenat MTB Plus检测法和培养法的检测阳性率分别为3.7%(27份)、8.2%(60份)、7.1%(52份)。在60例Truenat MTB Plus检测呈阳性的TB患者中,33例(55%)为PTB,27例(45%)为EPTB。我们估计Truenat MTB Plus检测法检测PTB的总体敏感性和特异性分别为90%(95%CI:73.4 - 97.8)和98.2%(95%CI:96 - 99.3)。EPTB的总体敏感性和特异性分别为81.8%(95%CI:59.7 - 94.8)和97.4%(95%CI:95.1 - 98.8)。
Truenat MTB Plus检测法具有与其他分子检测法相当的诊断准确性。Truenat MTB Plus检测法可用于PTB和EPTB的诊断,尤其是在资源有限的环境中。